Development of methodology for conducting clinical trials in frontotemporal lobar degeneration

David S Knopman, Joel H. Kramer, Bradley F Boeve, Richard John Caselli, Neill R Graff Radford, Mario F. Mendez, Bruce L. Miller, Nathaniel Mercaldo

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

To design clinical trials for the frontotemporal lobar degenerations (FTLD), knowledge about measurement of disease progression is needed to estimate power and enable the choice of optimal outcome measures. The aim here was to conduct a multicentre, 1 year replica of a clinical trial in patients with one of four FTLD syndromes, behavioural variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia (PNFA), progressive logopenic aphasia (PLA) and semantic dementia (SMD). Patients with one of the four FTLD syndromes were recruited from five academic medical centres over a 2 year period. Standard operationalized diagnostic criteria were used. In addition to clinical inclusion and exclusion criteria, patients were required to exhibit focal frontal, temporal or insular brain atrophy or dysfunction by neuroimaging. Patients underwent neuropsychological, functional, behavioural, neurological and MR imaging assessment at baseline and approximately 12 months later. Potential outcome measures were examined for their rates of floor and ceiling values at baseline and end of study, their mean changes and variances. The neuropsychological tests were combined into two cognitive composites - one for language functions and the other for executive functions. There were 107 patients who underwent baseline assessment and 78 who completed a follow-up assessment within 10-16 months. Two global measures, the FTLD-modified Clinical Dementia Rating (FTLD-modified CDR) and the Clinical Global Impression of Change (CGIC) demonstrated decline in the majority of patients. Several cognitive measures showed negligible floor or ceiling scores either at baseline or follow-up. Scores declined at follow-up in the majority of patients. The cognitive, executive and combined composites were shown to be sensitive to change across all FTLD syndromes. Patients improved at follow-up on the behavioural scales - the Frontal Behavioural Inventory (22%) and the Neuropsychiatric Inventory (28%) - suggesting that these instruments may not be ideal for clinical trial use. It was feasible to recruit FTLD patients in a simulated multi-centre trial. There are several candidate outcome measures - including the FTLD-CDR and the cognitive composites - that could be used in clinical trials across the spectrum of FTLD.

Original languageEnglish (US)
Pages (from-to)2957-2968
Number of pages12
JournalBrain
Volume131
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Frontotemporal Lobar Degeneration
Clinical Trials
Frontotemporal Dementia
Outcome Assessment (Health Care)
Primary Progressive Nonfluent Aphasia
Equipment and Supplies
Neuropsychological Tests
Aphasia
Executive Function
Neuroimaging
Atrophy
Dementia
Disease Progression
Language

Keywords

  • Clinical trials
  • Frontotemporal dementia
  • Neuropsychology

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. / Knopman, David S; Kramer, Joel H.; Boeve, Bradley F; Caselli, Richard John; Graff Radford, Neill R; Mendez, Mario F.; Miller, Bruce L.; Mercaldo, Nathaniel.

In: Brain, Vol. 131, No. 11, 11.2008, p. 2957-2968.

Research output: Contribution to journalArticle

Knopman, David S ; Kramer, Joel H. ; Boeve, Bradley F ; Caselli, Richard John ; Graff Radford, Neill R ; Mendez, Mario F. ; Miller, Bruce L. ; Mercaldo, Nathaniel. / Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. In: Brain. 2008 ; Vol. 131, No. 11. pp. 2957-2968.
@article{03f5b8408c9f4c7cb96c03714de6c148,
title = "Development of methodology for conducting clinical trials in frontotemporal lobar degeneration",
abstract = "To design clinical trials for the frontotemporal lobar degenerations (FTLD), knowledge about measurement of disease progression is needed to estimate power and enable the choice of optimal outcome measures. The aim here was to conduct a multicentre, 1 year replica of a clinical trial in patients with one of four FTLD syndromes, behavioural variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia (PNFA), progressive logopenic aphasia (PLA) and semantic dementia (SMD). Patients with one of the four FTLD syndromes were recruited from five academic medical centres over a 2 year period. Standard operationalized diagnostic criteria were used. In addition to clinical inclusion and exclusion criteria, patients were required to exhibit focal frontal, temporal or insular brain atrophy or dysfunction by neuroimaging. Patients underwent neuropsychological, functional, behavioural, neurological and MR imaging assessment at baseline and approximately 12 months later. Potential outcome measures were examined for their rates of floor and ceiling values at baseline and end of study, their mean changes and variances. The neuropsychological tests were combined into two cognitive composites - one for language functions and the other for executive functions. There were 107 patients who underwent baseline assessment and 78 who completed a follow-up assessment within 10-16 months. Two global measures, the FTLD-modified Clinical Dementia Rating (FTLD-modified CDR) and the Clinical Global Impression of Change (CGIC) demonstrated decline in the majority of patients. Several cognitive measures showed negligible floor or ceiling scores either at baseline or follow-up. Scores declined at follow-up in the majority of patients. The cognitive, executive and combined composites were shown to be sensitive to change across all FTLD syndromes. Patients improved at follow-up on the behavioural scales - the Frontal Behavioural Inventory (22{\%}) and the Neuropsychiatric Inventory (28{\%}) - suggesting that these instruments may not be ideal for clinical trial use. It was feasible to recruit FTLD patients in a simulated multi-centre trial. There are several candidate outcome measures - including the FTLD-CDR and the cognitive composites - that could be used in clinical trials across the spectrum of FTLD.",
keywords = "Clinical trials, Frontotemporal dementia, Neuropsychology",
author = "Knopman, {David S} and Kramer, {Joel H.} and Boeve, {Bradley F} and Caselli, {Richard John} and {Graff Radford}, {Neill R} and Mendez, {Mario F.} and Miller, {Bruce L.} and Nathaniel Mercaldo",
year = "2008",
month = "11",
doi = "10.1093/brain/awn234",
language = "English (US)",
volume = "131",
pages = "2957--2968",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Development of methodology for conducting clinical trials in frontotemporal lobar degeneration

AU - Knopman, David S

AU - Kramer, Joel H.

AU - Boeve, Bradley F

AU - Caselli, Richard John

AU - Graff Radford, Neill R

AU - Mendez, Mario F.

AU - Miller, Bruce L.

AU - Mercaldo, Nathaniel

PY - 2008/11

Y1 - 2008/11

N2 - To design clinical trials for the frontotemporal lobar degenerations (FTLD), knowledge about measurement of disease progression is needed to estimate power and enable the choice of optimal outcome measures. The aim here was to conduct a multicentre, 1 year replica of a clinical trial in patients with one of four FTLD syndromes, behavioural variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia (PNFA), progressive logopenic aphasia (PLA) and semantic dementia (SMD). Patients with one of the four FTLD syndromes were recruited from five academic medical centres over a 2 year period. Standard operationalized diagnostic criteria were used. In addition to clinical inclusion and exclusion criteria, patients were required to exhibit focal frontal, temporal or insular brain atrophy or dysfunction by neuroimaging. Patients underwent neuropsychological, functional, behavioural, neurological and MR imaging assessment at baseline and approximately 12 months later. Potential outcome measures were examined for their rates of floor and ceiling values at baseline and end of study, their mean changes and variances. The neuropsychological tests were combined into two cognitive composites - one for language functions and the other for executive functions. There were 107 patients who underwent baseline assessment and 78 who completed a follow-up assessment within 10-16 months. Two global measures, the FTLD-modified Clinical Dementia Rating (FTLD-modified CDR) and the Clinical Global Impression of Change (CGIC) demonstrated decline in the majority of patients. Several cognitive measures showed negligible floor or ceiling scores either at baseline or follow-up. Scores declined at follow-up in the majority of patients. The cognitive, executive and combined composites were shown to be sensitive to change across all FTLD syndromes. Patients improved at follow-up on the behavioural scales - the Frontal Behavioural Inventory (22%) and the Neuropsychiatric Inventory (28%) - suggesting that these instruments may not be ideal for clinical trial use. It was feasible to recruit FTLD patients in a simulated multi-centre trial. There are several candidate outcome measures - including the FTLD-CDR and the cognitive composites - that could be used in clinical trials across the spectrum of FTLD.

AB - To design clinical trials for the frontotemporal lobar degenerations (FTLD), knowledge about measurement of disease progression is needed to estimate power and enable the choice of optimal outcome measures. The aim here was to conduct a multicentre, 1 year replica of a clinical trial in patients with one of four FTLD syndromes, behavioural variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia (PNFA), progressive logopenic aphasia (PLA) and semantic dementia (SMD). Patients with one of the four FTLD syndromes were recruited from five academic medical centres over a 2 year period. Standard operationalized diagnostic criteria were used. In addition to clinical inclusion and exclusion criteria, patients were required to exhibit focal frontal, temporal or insular brain atrophy or dysfunction by neuroimaging. Patients underwent neuropsychological, functional, behavioural, neurological and MR imaging assessment at baseline and approximately 12 months later. Potential outcome measures were examined for their rates of floor and ceiling values at baseline and end of study, their mean changes and variances. The neuropsychological tests were combined into two cognitive composites - one for language functions and the other for executive functions. There were 107 patients who underwent baseline assessment and 78 who completed a follow-up assessment within 10-16 months. Two global measures, the FTLD-modified Clinical Dementia Rating (FTLD-modified CDR) and the Clinical Global Impression of Change (CGIC) demonstrated decline in the majority of patients. Several cognitive measures showed negligible floor or ceiling scores either at baseline or follow-up. Scores declined at follow-up in the majority of patients. The cognitive, executive and combined composites were shown to be sensitive to change across all FTLD syndromes. Patients improved at follow-up on the behavioural scales - the Frontal Behavioural Inventory (22%) and the Neuropsychiatric Inventory (28%) - suggesting that these instruments may not be ideal for clinical trial use. It was feasible to recruit FTLD patients in a simulated multi-centre trial. There are several candidate outcome measures - including the FTLD-CDR and the cognitive composites - that could be used in clinical trials across the spectrum of FTLD.

KW - Clinical trials

KW - Frontotemporal dementia

KW - Neuropsychology

UR - http://www.scopus.com/inward/record.url?scp=55749085637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749085637&partnerID=8YFLogxK

U2 - 10.1093/brain/awn234

DO - 10.1093/brain/awn234

M3 - Article

C2 - 18829698

AN - SCOPUS:55749085637

VL - 131

SP - 2957

EP - 2968

JO - Brain

JF - Brain

SN - 0006-8950

IS - 11

ER -